<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00100659</url>
  </required_header>
  <id_info>
    <org_study_id>67767 (completed)</org_study_id>
    <secondary_id>U01DK067767</secondary_id>
    <nct_id>NCT00100659</nct_id>
  </id_info>
  <brief_title>PEDS-C: Pegylated Interferon +/- Ribavirin for Children With Hepatitis C</brief_title>
  <official_title>Pegylated Interferon +/- Ribavirin for Children With Hepatitis C</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and efficacy of peginterferon alfa-2a
      (PEG-2a) in combination with ribavirin (RV) and PEG-2a alone for the treatment of chronic
      hepatitis C virus (CHC) infection in children.

      The purpose of this study is also to determine whether PEG-2a in combination with RV or
      PEG-2a alone will result in a longer response rate in children with CHC.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sustained Viral Response (SVR)</measure>
    <time_frame>at least 24 weeks after stopping treatment.</time_frame>
    <description>SVR is defined as nondetectable hepatitis C virus ribonucleic acid (HCV RNA) in plasma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>At any time up to 72 weeks</time_frame>
    <description>Influenza-like, headache, and gastrointestinal symptoms</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">114</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Pegylated interferon/ribavirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pegasys - 180 mcg per 1.73 meter squared body surface area subcutaneously once weekly.
Ribavirin - 15 mg per kg orally twice daily using 100-mg tablets.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pegylated interferon/placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets were supplied in the same dosing regimen as ribavirin, using the same number of tablets that would be given if ribavirin were being administered (eg, 3 placebo tablets twice daily for a 40-kg child who would receive 3 100-mg RV tablets twice daily).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated Interferon/ribavirin</intervention_name>
    <arm_group_label>Pegylated interferon/placebo</arm_group_label>
    <arm_group_label>Pegylated interferon/ribavirin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients who are 5-18 years of age at enrollment (not yet reached 18th
             birthday at screening).

          -  HCV viremia (by any test) present on 2 tests separated by at least 6 months.

          -  Chronic liver disease, as indicated by inflammation and/or fibrosis, consistent with
             chronic hepatitis C infection on a liver biopsy obtained within the past 24 months, as
             assessed by a qualified pathologist, not consistent with other known liver disease and
             not normal.

          -  Compensated liver disease (Child-Pugh Grade A clinical classification)

          -  Signed informed consent from parent/legal guardian and willingness of parent/legal
             guardian to abide by the requirements of the study.

          -  Hemoglobin values &gt;11 g/dL for females; &gt; 12 g/dL for males

          -  Normal thyroid stimulating hormone (TSH)

          -  Able to swallow a ribavirin/placebo tablet

        Exclusion Criteria:

          -  Any prior treatment with Interferon or ribavirin (RV)

          -  Receipt of any investigational drug &lt;6 weeks prior to the first dose of study drug

          -  Any systemic antiviral therapy &lt;6 weeks prior to the first dose of study drug.
             Exception: patients who have taken or are expected to require acyclovir for herpetic
             lesions

          -  Positive test at screening for anti-HAV IgM Ab, HBsAg, anti-HBc IgM Ab, or anti-HIV Ab

          -  History or other evidence of a medical condition associated with chronic liver disease
             other than HCV (abnormal ceruloplasmin, alpha-1-antitrypsin, ANA&gt;1:160, SMA&gt;1:80,
             anti-LKM antibody &gt; 60 units))

          -  History or other evidence of bleeding from esophageal varices

          -  Decompensated liver disease (e.g. conjugated bilirubin &gt;1.5mg/dl, ascites, varices,
             Child-Pugh Grade B or C clinical classification)

          -  History of autoimmune or immunologically mediated disease (e.g. inflammatory bowel
             disease, idiopathic thrombocytopenic purpura, lupus erythematosus, autoimmune
             hemolytic anemia, scleroderma, severe psoriasis, clinical evidence of rheumatoid
             arthritis)

          -  Absolute neutrophil count &lt;1500 cells/mm3 , hemoglobin &lt;11 g/dL for females and &lt;12
             g/dL for males, white blood count&gt;17.5 x 109/L, or platelet count &lt;90,000/ mm3

          -  Serum creatinine level &gt;1.5 times the upper limit of normal for age

          -  Major depression according to the American Psychiatric Association, or a history of
             severe psychiatric disorder, such as major psychoses, suicidal ideation and/or suicide
             attempt

          -  History or other evidence of chronic pulmonary or cardiac disease associated with
             functional limitation

          -  History of thyroid disease poorly controlled on prescribed medications. Patients with
             elevated thyroid stimulating hormone (TSH) concentrations with elevation of antibodies
             to thyroid peroxidase and any clinical manifestations of thyroid disease are excluded

          -  Poorly controlled diabetes as defined by glycosylated hemoglobin of &gt; 8%

          -  History of solid organ or bone marrow transplantation

          -  Evidence of severe retinopathy

          -  Coagulopathy (international normalized ratio&gt;1.5)

          -  Evidence of an active or suspected cancer or a history of malignancy where the risk of
             recurrence is &gt;20% within 2 years.

          -  Hemoglobinopathy

          -  Hemophilia

          -  Severe retinopathy

          -  History of other evidence of severe illness or any other conditions which would make
             the patient, in the opinion of the investigator, unsuitable for the study

          -  Sexually active females of child-bearing potential (defined as age 10 years and older)
             and sexually active men who are not practicing two forms of effective contraception
             during treatment and during the 6 months after treatment has been concluded

          -  Females who have a positive serum pregnancy test within 7 days of initiation of
             treatment or who are breast-feeding

          -  Males whose female partners are pregnant

          -  Active substance abuse

          -  A sibling and/or any other child living in the same household or sharing the same
             primary caregiver enrolled in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kathleen B Schwarz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-0136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University School of Medicine, James Whitcomb Riley Hospital for Children</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202-5225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital and Regional Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Murray KF, Rodrigue JR, González-Peralta RP, Shepherd J, Barton BA, Robuck PR, Schwarz KB; PEDS-C Clinical Research Network. Design of the PEDS-C trial: pegylated interferon +/- ribavirin for children with chronic hepatitis C viral infection. Clin Trials. 2007;4(6):661-73.</citation>
    <PMID>18042575</PMID>
  </reference>
  <results_reference>
    <citation>Rodrigue JR, Balistreri W, Haber B, Jonas MM, Mohan P, Molleston JP, Murray KF, Narkewicz MR, Rosenthal P, Smith LJ, Lobritto SJ, Schwarz KB, Robuck PR, Barton B, González-Peralta RP. Peginterferon with or without ribavirin has minimal effect on quality of life, behavioral/emotional, and cognitive outcomes in children. Hepatology. 2011 May;53(5):1468-75. doi: 10.1002/hep.24248.</citation>
    <PMID>21351116</PMID>
  </results_reference>
  <results_reference>
    <citation>Schwarz KB, Gonzalez-Peralta RP, Murray KF, Molleston JP, Haber BA, Jonas MM, Rosenthal P, Mohan P, Balistreri WF, Narkewicz MR, Smith L, Lobritto SJ, Rossi S, Valsamakis A, Goodman Z, Robuck PR, Barton BA; Peds-C Clinical Research Network. The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents with chronic hepatitis C. Gastroenterology. 2011 Feb;140(2):450-458.e1. doi: 10.1053/j.gastro.2010.10.047. Epub 2010 Oct 28.</citation>
    <PMID>21036173</PMID>
  </results_reference>
  <results_reference>
    <citation>Goodman ZD, Makhlouf HR, Liu L, Balistreri W, Gonzalez-Peralta RP, Haber B, Jonas MM, Mohan P, Molleston JP, Murray KF, Narkewicz MR, Rosenthal P, Smith LJ, Robuck PR, Schwarz KB. Pathology of chronic hepatitis C in children: liver biopsy findings in the Peds-C Trial. Hepatology. 2008 Mar;47(3):836-43. doi: 10.1002/hep.22094.</citation>
    <PMID>18167062</PMID>
  </results_reference>
  <results_reference>
    <citation>Narkewicz MR, Rosenthal P, Schwarz KB, Drack A, Margolis T, Repka MX; PEDS-C Study Group. Ophthalmologic complications in children with chronic hepatitis C treated with pegylated interferon. J Pediatr Gastroenterol Nutr. 2010 Aug;51(2):183-6. doi: 10.1097/MPG.0b013e3181b99cf0.</citation>
    <PMID>20512062</PMID>
  </results_reference>
  <results_reference>
    <citation>Delgado-Borrego A, Gonzalez-Peralta RP, Raza R, Negre B, Goodman ZD, Jonas MM, Chung RT, Ludwig DA; PEDS-C Clinical Research Network. Correlates of adiponectin in hepatitis C-infected children: the importance of body mass index. J Pediatr Gastroenterol Nutr. 2015 Feb;60(2):165-70. doi: 10.1097/MPG.0000000000000604.</citation>
    <PMID>25313851</PMID>
  </results_reference>
  <results_reference>
    <citation>Schwarz KB, Molleston JP, Jonas MM, Wen J, Murray KF, Rosenthal P, Gonzalez-Peralta RP, Lobritto SJ, Mogul D, Pavlovic V, Warne C, Wat C, Thompson B. Durability of Response in Children Treated With Pegylated Interferon alfa [corrected] 2a ± Ribavirin for Chronic Hepatitis C. J Pediatr Gastroenterol Nutr. 2016 Jan;62(1):93-6. doi: 10.1097/MPG.0000000000000929. Erratum in: J Pediatr Gastroenterol Nutr. 2016 Feb;62(2):357. J Pediatr Gastroenterol Nutr. 2016 Jan 11;:.</citation>
    <PMID>26284539</PMID>
  </results_reference>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>January 4, 2005</study_first_submitted>
  <study_first_submitted_qc>January 4, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2005</study_first_posted>
  <results_first_submitted>May 10, 2013</results_first_submitted>
  <results_first_submitted_qc>May 10, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 1, 2013</results_first_posted>
  <last_update_submitted>September 24, 2018</last_update_submitted>
  <last_update_submitted_qc>September 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pediatric</keyword>
  <keyword>hepatitis</keyword>
  <keyword>children</keyword>
  <keyword>HCV</keyword>
  <keyword>PEG</keyword>
  <keyword>PEG-2a</keyword>
  <keyword>peginterferon alfa-2a</keyword>
  <keyword>Pegylated Interferon</keyword>
  <keyword>RV</keyword>
  <keyword>ribavirin</keyword>
  <keyword>Pegasys</keyword>
  <keyword>CHC</keyword>
  <keyword>chronic hepatitis C</keyword>
  <keyword>chronic hepatitis C virus</keyword>
  <keyword>hepatitis c</keyword>
  <keyword>pediatric hepatitis</keyword>
  <keyword>pediatric HCV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Ribavirin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Protocols, manuals, and data will be posted at the NIDDK Central Repository</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Data were posted to the NIDDK Central Repository in March 2013.</ipd_time_frame>
    <ipd_access_criteria>Data can be requested from the NIDDK Central Repository. A signed data use agreement is required.</ipd_access_criteria>
    <ipd_url>https://repository.niddk.nih.gov/studies/peds-c/?query=peds-c</ipd_url>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>December 2004 to May 2006 at 11 US medical centers</recruitment_details>
      <pre_assignment_details>Failure to meet inclusion criteria</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Pegylated Interferon/Ribavirin</title>
          <description>Pegasys - 180 mcg per 1.73 meter squared body surface area subcutaneously once weekly.
Ribavirin - 15 mg per kg orally twice daily using 100-mg tablets.</description>
        </group>
        <group group_id="P2">
          <title>Pegylated Interferon/Placebo</title>
          <description>Placebo tablets were supplied in the same dosing regimen as ribavirin (RV), using the same number of tablets that would be given if ribavirin were being administered (eg, 3 placebo tablets twice daily for a 40-kg child who would receive 3 100-mg RV tablets twice daily).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pegylated Interferon/Ribavirin</title>
          <description>Pegasys - 180 mcg per 1.73 meter squared body surface area subcutaneously once weekly.
Ribavirin - 15 mg per kg orally twice daily using 100-mg tablets.</description>
        </group>
        <group group_id="B2">
          <title>Pegylated Interferon/Placebo</title>
          <description>Placebo tablets were supplied in the same dosing regimen as ribavirin, using the same number of tablets that would be given if ribavirin were being administered (eg, 3 placebo tablets twice daily for a 40-kg child who would receive 3 100-mg RV tablets twice daily).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="55"/>
            <count group_id="B2" value="59"/>
            <count group_id="B3" value="114"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="114"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.7" spread="3.3"/>
                    <measurement group_id="B2" value="10.8" spread="3.6"/>
                    <measurement group_id="B3" value="10.75" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="51"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sustained Viral Response (SVR)</title>
        <description>SVR is defined as nondetectable hepatitis C virus ribonucleic acid (HCV RNA) in plasma</description>
        <time_frame>at least 24 weeks after stopping treatment.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PEG/RV</title>
            <description>Pegylated interferon/ribavirin</description>
          </group>
          <group group_id="O2">
            <title>PEG/Placebo</title>
            <description>Pegylated interferon/placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Sustained Viral Response (SVR)</title>
          <description>SVR is defined as nondetectable hepatitis C virus ribonucleic acid (HCV RNA) in plasma</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events</title>
        <description>Influenza-like, headache, and gastrointestinal symptoms</description>
        <time_frame>At any time up to 72 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pegylated Interferon/Ribavirin</title>
            <description>Pegasys - 180 mcg per 1.73 meter squared body surface area subcutaneously once weekly.
Ribavirin - 15 mg per kg orally twice daily using 100-mg tablets.
Pegylated Interferon/ribavirin</description>
          </group>
          <group group_id="O2">
            <title>Pegylated Interferon/Placebo</title>
            <description>Placebo tablets were supplied in the same dosing regimen as ribavirin, using the same number of tablets that would be given if ribavirin were being administered (eg, 3 placebo tablets twice daily for a 40-kg child who would receive 3 100-mg RV tablets twice daily).
Pegylated Interferon/ribavirin</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <description>Influenza-like, headache, and gastrointestinal symptoms</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Influenza-like symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Pegylated Interferon/Ribavirin</title>
          <description>Pegasys - 180 mcg per 1.73 meter squared body surface area subcutaneously once weekly.
Ribavirin - 15 mg per kg orally twice daily using 100-mg tablets.</description>
        </group>
        <group group_id="E2">
          <title>Pegylated Interferon/Placebo</title>
          <description>Placebo tablets were supplied in the same dosing regimen as ribavirin, using the same number of tablets that would be given if ribavirin were being administered (eg, 3 placebo tablets twice daily for a 40-kg child who would receive 3 100-mg RV tablets twice daily).</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>New onset diabetes mellitus Type 1</sub_title>
                <description>Hospitalization</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Complications of a liver biopsy</sub_title>
                <description>Hospitalization and cholecystectomy</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicide gesture</sub_title>
                <description>Hospitalization</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal symptoms</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Flu-like symptoms</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Trouble sleeping</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Joint and muscle aches</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Itching</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Kathleen B. Schwarz, M.D.</name_or_title>
      <organization>Johns Hopkins University School of Medicine</organization>
      <phone>410-955-8769</phone>
      <email>kschwarz@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

